David Zaccardelli - 05 Jan 2026 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ Grant Levine, attorney-in-fact
Issuer symbol
SABS
Transactions as of
05 Jan 2026
Net transactions value
$0
Form type
4
Filing time
07 Jan 2026, 16:40:03 UTC
Previous filing
08 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ZACCARDELLI DAVID Director 777 W 41ST STREET, SUITE 401, MIAMI BEACH /s/ Grant Levine, attorney-in-fact 07 Jan 2026 0001627642

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Stock Option (right to buy) Award $0 +240,000 $0.000000 240,000 05 Jan 2026 Common Stock 240,000 $3.74 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.
F2 This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.